Details for Patent: 10,858,341
✉ Email this page to a colleague
Which drugs does patent 10,858,341 protect, and when does it expire?
Patent 10,858,341 protects AZSTARYS and is included in one NDA.
This patent has twenty-three patent family members in seventeen countries.
Summary for Patent: 10,858,341
| Title: | Compositions comprising methylphenidate-prodrugs, processes of making and using the same |
| Abstract: | The present technology is directed to compositions comprising d-threo-methylphenidate conjugates and unconjugated methylphenidate. The present technology also relates to compositions and oral formulations comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof. The present technology additionally relates to a pharmaceutical kit containing the composition comprising d-threo-methylphenidate conjugated to nicotinoyl-L-serine, and/or a pharmaceutically acceptable salt thereof, and unconjugated methylphenidate and/or a pharmaceutically acceptable salt thereof. |
| Inventor(s): | Mickle; Travis (Kissimmee, FL), Guenther; Sven (Coralville, IA), Chi; Guochen (Coralville, IA) |
| Assignee: | KemPharm, Inc. (Celebration, FL) |
| Application Number: | 16/793,923 |
|
Patent Claim Types: see list of patent claims | Use; Composition; Formulation; Dosage form; |
Drugs Protected by US Patent 10,858,341
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Patented / Exclusive Use | Submissiondate |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Commave Therap | AZSTARYS | dexmethylphenidate hydrochloride; serdexmethylphenidate chloride | CAPSULE;ORAL | 212994-001 | May 7, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE | ⤷ Sign Up | ||||
| Commave Therap | AZSTARYS | dexmethylphenidate hydrochloride; serdexmethylphenidate chloride | CAPSULE;ORAL | 212994-002 | May 7, 2021 | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE | ⤷ Sign Up | ||||
| Commave Therap | AZSTARYS | dexmethylphenidate hydrochloride; serdexmethylphenidate chloride | CAPSULE;ORAL | 212994-003 | May 7, 2021 | RX | Yes | Yes | ⤷ Sign Up | ⤷ Sign Up | TREATMENT OF ATTENTION-DEFICIT HYPERACTIVITY DISORDER (ADHD) WITH SERDEXMETHYLPHENIDATE AND DEXMETHYLPHENIDATE | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Patented / Exclusive Use | >Submissiondate |
International Family Members for US Patent 10,858,341
| Country | Patent Number | Estimated Expiration | Supplementary Protection Certificate | SPC Country | SPC Expiration |
|---|---|---|---|---|---|
| Australia | 2017371327 | ⤷ Sign Up | |||
| Australia | 2020239746 | ⤷ Sign Up | |||
| Brazil | 112019011640 | ⤷ Sign Up | |||
| Canada | 3046486 | ⤷ Sign Up | |||
| China | 110234636 | ⤷ Sign Up | |||
| Denmark | 3551619 | ⤷ Sign Up | |||
| European Patent Office | 3551619 | ⤷ Sign Up | |||
| >Country | >Patent Number | >Estimated Expiration | >Supplementary Protection Certificate | >SPC Country | >SPC Expiration |
